Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Colistin (Polymyxin E) vs Eptifibatide (Integrilin)
An educational, source-based comparison of Colistin (Polymyxin E) and Eptifibatide (Integrilin) — how each peptide works, what it's researched for, and what to know before going deeper.
Last-resort lipopeptide antibiotic for multidrug-resistant Gram-negatives.
Cationic cyclic lipopeptide that disrupts the outer membrane of Gram-negative bacteria by binding lipid A of LPS, causing membrane permeability and cell death.
- Carbapenem-resistant Acinetobacter, Klebsiella, Pseudomonas
- • FDA-approved.
- • Nephrotoxicity and neurotoxicity dose-limiting.
GP IIb/IIIa inhibitor cyclic peptide for ACS and PCI.
Cyclic heptapeptide derived from rattlesnake venom that reversibly blocks platelet glycoprotein IIb/IIIa receptors, preventing fibrinogen binding and platelet aggregation.
- Acute coronary syndromes
- PCI
- • FDA-approved.
- • Bleeding risk; renal adjustment required.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Colistin (Polymyxin E) | Colistin in MDR Gram-negative infections | Clinical Infectious Diseases | 2005 | Effective salvage therapy with manageable nephrotoxicity in modern dosing. |
| Eptifibatide (Integrilin) | PURSUIT trial | NEJM | 1998 | Reduced death/MI in non-ST-elevation ACS. |
Side-effect & safety grid
- FDA-approved.
- Nephrotoxicity and neurotoxicity dose-limiting.
- FDA-approved.
- Bleeding risk; renal adjustment required.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Colistin (Polymyxin E) vs Eptifibatide (Integrilin) — Key differences
- Class: Colistin (Polymyxin E) is classified as Polymyxin · Infectious Disease, while Eptifibatide (Integrilin) is Antiplatelet · Cardiology.
- Primary research focus: Colistin (Polymyxin E) — carbapenem-resistant acinetobacter, klebsiella, pseudomonas; Eptifibatide (Integrilin) — acute coronary syndromes.
- Tag: FDA-Approved · Antibiotic vs FDA-Approved · Cardiology.